EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
ERIC European Research Infrastructure Consortium

- Legal form - directly applicable across EU
- Independent & non-commercial
- Long term commitment of member governments

EU-LAC HEALTH has received funding from the European Union`s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
EATRIS members

Participating countries:
CZ, DK, ES, FI, FR, IT, NO, EE, NL (Host)

Negotiations ongoing with: BE, DE, PT, SI, SE, TR, UK

70+ Academic & non-profit research institutions of excellence in translational medicine

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
EATRIS Positioning

• **Vision**
  - Making translation of scientific discoveries into medical products more effective to improve human health and quality of life.

• **Mission**
  - To support our clients in developing their biomedical discoveries for novel preventive, diagnostic or therapeutic products up to clinical proof of concept.

• **Supporting academia, funders, SME & biotech/pharma**

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
Components of the translational pathway

**Clients**
- Academia
- Research/charities
- SME/biotech
- Pharma
- Nat’l governments
- Regional dev. Funds
- H2020
- Venture capital
- Pharma partnering

**Client projects**

**Infrastructure**
- GMP manufacturing
- Product platforms
- Biobanks
- Clinical trial units
- Patient groups

**Funding**

**Expertise**
- Clinicians
- Technologies
- Biomarkers
- Regulatory
- IP, partnering

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 281459.
Infrastructure: Product Platforms

- EATRIS is organized following the pharmaceutical industry pipeline model:

  - Medicinal products
    - Small Chemical Entities,
    - Vaccines
    - Advanced Therapy Medicinal Product (Biologicals)

  - Supporting Technologies and Medical Devices
    - Imaging and Tracers
    - Biomarkers

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 281459.
Project initiation and implementation

1. Translational Assessment
   - Core C&S activity
   - Involve expert reviewers as needed
   - Involve P.I. & his/her TTO

2. Matchmaking
   - Database identifies relevant infrastructure, disease knowledge and patient cohorts
   - P.I. has lead in selecting partners

3. Exploration
   - Institutes explore project with P.I.
   - Project team assembled, including experts
   - Product Development Plan created

4. Initiation
   - Define steps, milestones, budgets
   - Draw up bilateral contracts - from template
   - Start multi-step, multi-party international project

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
Why a Research Infrastructure in Translational Medicine?
The need and the challenge

The role of the Industry

• Successful. In the last 60 years an increase of the average human lifespan from 35 to 75 years.

The need for Academic Science

• Innovative and impartial, pushing the boundaries of knowledge for the sake of knowledge.
The Innovation Gap

- Biopharmaceutical R&D today
- Pipeline productivity stalling
- Industry early R&D moving to acquisition
- Funds for research drying up
- High fundamental output – little innovation
- Substantial expertise – severely fragmented
- Variable collaboration experience
What is the main challenge for an effective Translational Medicine today?

Cost
EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nº 281459.

Funding availability

Available funding

Stage of development

Basic | Translation Phase | Clinical Development
Facilitating efficient collaboration

To make collaboration faster & less risky:

• 70 translational institutes under 1 framework agreement (EATRIS Framework Agreement)
  • Common IP policy
  • Harmonised quality framework
  • Standardised operational framework
  • Template agreements under development
• Faster time to contract, support in negotiating & IP
• One-on-one client/institute contract - no liability or IP issues
• Efficient links to complete innovation pathway, industry
Reduce Risk – increase the output

• Only high potential projects selected for development – *reduce failure rate*

• Executed by top quality infrastructure with track record – *reduce systemic risk*

• Optimal strategy with early imaging, biomarker, clinical, regulatory, input – *maximise resource efficiency*

• Seamless transition to external partners/collaborators – *Reduce transactional risk & lead times*

➢ Higher output per research Euro
➢ Better medicine

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nº 281459.
A strategy for International collaboration?
Collaborations between EATRIS Institutes and Latin America

- Ongoing projects between Institutes also participating to EATRIS and the LAC area
- Mainly, single scientific project often based on personal connection or exchange program for young scientist / physicians

EU-LAC HEALTH has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 281459.
Worldwide challenges

• Challenges are not limited only by cost
  • Commitment to treat Poverty Related Diseases (Your diseases were, or will be, mine too)
  • Rare patients are many worldwide (potential market)

• but also by biological resources
  – Access to biological samples and data for emerging diseases
Benefits from coordination

Sharing the cost and the rewards make sense in a time of scarcity.

Health improvement is costly but healthy individuals remain productive.

A role for common good based capitalism has to be identified.

EU-LAC HEALTH has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 281459.
EU-LAC Health Partners

Dr. Rafael de Andrés (Coordinator)
ISCIII, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain

Dr. Luis Tacsan Chen
RIMAI, Red Iberoamericana Ministerial de Aprendizaje e Investigación en Salud, Ministerio de Salud, Costa Rica

Dr. Joaquin Guinea
INNOVATEC, Sociedad para el Fomento de la Innovación Tecnológica, Spain

Dr. Gabriela Montorzi
COHRED, Council on Health Research for Development, Switzerland /Mexico

Dr. Stephanie Splett-Rudolph
DLR, Deutsches Zentrum für Luft- und Raumfahrt e.V., Germany

Dr. Paulo Buss
FIOCRUZ, Fundación Oswaldo Cruz, Brazil

Eng. Águeda Menvielle
MINCYT, Ministerio de Ciencia, Tecnología Argentina e Innovación Productiva

Dr. Diassina Di Maggio
APRE, Agenzia per la Promozione della Ricerca, Italy

EU-LAC HEALTH has received funding from the European Union`s Seventh Framework Programme (FP7/2007-2013) under grant agreement n. 281459.